Platinum-based chemotherapy in triple-negative breast cancer

被引：170

作者：

Sirohi, B. ^{[1
]}

Arnedos, M. ^{[1
]}

Popat, S. ^{[1
]}

Ashley, S. ^{[1
]}

Nerurkar, A. ^{[1
]}

Walsh, G. ^{[1
]}

Johnston, S. ^{[1
]}

Smith, I. E. ^{[1
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Breast Unit, London SW3 6JJ, England

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷 / 11期

关键词：

breast cancer; early and advanced; platinum chemotherapy; triple-negative;

D O I：

10.1093/annonc/mdn395

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Experimental data suggest that triple-negative (TN) breast cancer may have increased sensitivity to platinum-based chemotherapy but clinical data are limited. We present our long-term results with platinum-based chemotherapy for TN breast cancer. Patients and methods: In all, 94 (17 TN), 79 (11 TN) and 155 (34 TN) patients receiving platinum-based chemotherapy in neo-adjuvant/adjuvant and advanced setting were included. Response rates and outcome were compared for TN tumours versus others. Results: Neo-adjuvant complete response rates were significantly higher for TN tumours (88%) than others (51%; P = 0.005). The 5-year overall survival (OS) for TN tumours following adjuvant/neo-adjuvant chemotherapy was 64% [95% confidence interval (CI) 44% to 79%] compared with 85% (95% CI 79% to 90%) for others. Five-year disease-free survival for TN tumours was 57% (95% CI 37% to 73%) compared with 72% (95% CI 64% to 78%) for others. For patients with advanced breast cancer, overall response rates were 41% for TN tumours and 31% for others (P = 0.3). Patients with TN tumours had a significantly prolonged progression-free survival of 6 months compared with 4 months for others (P = 0.05), though the OS was not significantly different between the two groups (11 versus 7 months). Conclusion: Platinum-based chemotherapy achieves increased response rates for TN tumours, with a trend towards worse survival in early breast cancer through an improved survival in advanced disease. Prospective randomised trials are warranted.

引用

页码：1847 / 1852

页数：6

共 33 条

[21] CISPLATIN AS 1ST-LINE THERAPY FOR METASTATIC BREAST-CANCER [J].

SLEDGE, GW ;

LOEHRER, PJ ;

ROTH, BJ ;

EINHORN, LH .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) :1811-1814

[22]

Smith IE, 1998, RECENT RES CANCER, V152, P323

[23] CISPLATIN AND ITS ANALOGS IN THE TREATMENT OF ADVANCED BREAST-CANCER - A REVIEW [J].

SMITH, IE ;

TALBOT, DC .

BRITISH JOURNAL OF CANCER, 1992, 65 (06) :787-793

[24] A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial [J].

Smith, IE ;

A'Hern, RP ;

Coombes, GA ;

Howell, A ;

Ebbs, SR ;

Hickish, TF ;

O'Brien, MER ;

Mansi, JL ;

Wilson, CB ;

Robinson, AC ;

Murray, PA ;

Price, CGA ;

Perren, TJ ;

Laing, RW ;

Bliss, JM .

ANNALS OF ONCOLOGY, 2004, 15 (05) :751-758

[25] HIGH COMPLETE REMISSION RATES WITH PRIMARY NEOADJUVANT INFUSIONAL CHEMOTHERAPY FOR LARGE EARLY BREAST-CANCER [J].

SMITH, IE ;

WALSH, G ;

JONES, A ;

PRENDIVILLE, J ;

JOHNSTON, S ;

GUSTERSON, B ;

RAMAGE, F ;

ROBERTSHAW, H ;

SACKS, N ;

EBBS, S ;

MCKINNA, JA ;

BAUM, M .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) :424-429

[26] Repeated observation of breast tumor subtypes in independent gene expression data sets [J].

Sorlie, T ;

Tibshirani, R ;

Parker, J ;

Hastie, T ;

Marron, JS ;

Nobel, A ;

Deng, S ;

Johnsen, H ;

Pesich, R ;

Geisler, S ;

Demeter, J ;

Perou, CM ;

Lonning, PE ;

Brown, PO ;

Borresen-Dale, AL ;

Botstein, D .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (14) :8418-8423

[27] Breast cancer classification and prognosis based on gene expression profiles from a population-based study [J].

Sotiriou, C ;

Neo, SY ;

McShane, LM ;

Korn, EL ;

Long, PM ;

Jazaeri, A ;

Martiat, P ;

Fox, SB ;

Harris, AL ;

Liu, ET .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (18) :10393-10398

[28]

TAN DSP, 2007, BREAST CANC RES TREA

[29]

Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205

[30] Hallmarks of 'BRCAness' in sporadic cancers [J].

Turner, N ;

Tutt, A ;

Ashworth, A .

NATURE REVIEWS CANCER, 2004, 4 (10) :814-819

← 1 2 3 4 →